Introduction
Poly(ADP-ribosyl)ation is an early cellular response to DNA damage and is a concerted and dynamic process: poly(ADP-ribose) polymerases (PARPs) catalyze the transfer of poly(ADP-ribose) (pADPr) polymers and attach them to specific target proteins, whereas poly(ADPribose) glycohydrolase (PARG) rapidly hydrolyzes pADPr (1). So far, 22 genes encoding members of the PARP family have been identified (2, 3) , among which the most abundant and major polymerizing enzyme PARP1 has been extensively characterized. Genetic and molecular studies have demonstrated the involvement of PARP1 in DNA repair, genomic stability, chromatin functions, apoptosis and ageing, as well as in transcription regulation (4) (5) (6) (7) (8) 34) .
A chemical inhibition of PARP1 or genetic mutations of PARP1 cause a severe genomic instability phenotype, characterized by a high rate of sister chromatid exchange (SCE) and micronuclei formation, chromosomal aberration, centrosome amplification as well as telomere shortening (5, 6) . Cells lacking PARP1 are hypersensitive to methylnitrosourea and other genotoxic agents (10, 11) . Thus, poly(ADP-ribosy)lation has been considered to function in the surveillance of the genome after genotoxic insults. Because the degradation of pADPr following DNA damage has been ascribed to the activity of PARG, which occurs only a few minutes after its synthesis (12) , the transient nature of poly(ADP-ribosyl)ation is thus speculated to be an important regulatory means in various cellular processes. PARG is the only known enzyme to hydrolyze pADPr in the nucleus, whereas there are 22 different PARP members in the PARP superfamily (3) . Therefore, the delineation of the function of PARG provides a good opportunity in understanding the homeostasis of poly(ADP-ribosyl)ation in physiological conditions and PARG offers unique drug targets.
Two major isoforms of PARG, encoded by a single gene locus, have been documented in mice: the 110 kD isoform (PARG 110 ), localized in the nucleus and cytoplasm, is the major form of PARG, whereas the 60 kD isoform (PARG 60 ) is only found in the cytosolic fraction, which also harbors the pADPr-degrading activity (13, 14) . Loss of PARG function in Drosophila melanogaster results in progressive neurodegeneration with a reduced locomotor activity and a short lifespan due to the excessive production of pADPr in the central nervous system (15) . Strikingly, a null mutation of PARG in mice causes embryonic lethality in very early development (16) , which is probably due to the toxicity of excess of pADPr that induces the release of the apoptosis-inducing factor leading to cell death (17, 18) . Interestingly, mice and cells carrying the hypomorphic mutation of PARG, i.e. lacking the 110 kD isoform (PARG 110 À/À ), are viable and fertile (19) . Studies on these cellular and animal models have revealed the function of the PARG and pADPr metabolism in pathophysiological processes (13) , such as tissue injury of the kidney (20) , intestine (21, 22) , spinal cord (23) and the ischemia of brains (24) . Recent efforts have been focused on developing chemical inhibitors of PARG to modulate poly(ADP-ribose) homeostasis in order to develop therapeutic strategies to treat various pathological conditions in humans (14, 25) .
PARP1 plays an important role in base excision repair of singlestrand break (SSB) repair (26, 27) . PARP1-knockout studies or chemical inhibition of pADPr formation have implicated poly(ADPribosyl)ation and PARP1 in DNA repair, genomic instability and tumorigenesis (4) (5) (6) (7) . Given a tightly regulated homeostasis of poly(ADPribosyl)ation, the degrading enzyme PARG may be expected to have an important function in these processes. We previously showed that PARG 110 -deficient cells are hypersensitive to alkylating agents and c-irradiation (19, 28) and PARG À/À embryonic stem (ES) cells show an enhanced lethality after the treatment with dimethyl sulfate, cisplatin and c-ray irradiation (29) . These suggest that PARG is involved in DNA damage response. However, the exact cause of the cytotoxic phenotype has not been fully explored. In the present study, we focus our effort on delineating the role of PARG or poly(ADPribose) homeostasis in DNA damage response and in the maintenance of genomic stability by using mice and cells carrying a hypomorphic mutation of PARG (PARG 110 À/À ).
Materials and methods
Isolation and culture of primary mouse embryonic fibroblasts Primary mouse embryonic fibroblasts (MEFs) were isolated from intercrosses of PARG 110 þ/À mice in the 129/Sv background and cultured as described previously (11) . For experiments analyzing genomic instability and cell cycle progression, only cells at early passages ( 3) were used. To immortalize the MEFs, we followed the protocol described previously (11) .
Cell survival assay (colony formation) Immortalized wild-type (A19 and Pg198) and PARG 110 À/À (Pg192 and Pg196) MEFs were seeded at a density of 10 000/10 cm dish. Cells were challenged with the indicated doses of adriamycin for 3 h. Colonies formed were scored 10 days after culture.
Comet assay
In order to detect the DNA breaks after damage, an alkaline Comet assay was performed as described (30) . Primary MEF cells (passage 3) from wild-type and PARG 110 À/À mice were treated with 100 lM hydrogen peroxide (H 2 O 2 ) for 10 min or 20 Gy of c-ray irradiation. The tail moment after a single-cell electrophoresis was counted randomly for a total of 200 cells using the Comet Imager 1.2.10 software (MetaSystems, Altlussheim, Germany).
SCE and micronucleus assays
For the examination of SCEs, primary MEFs (passage 3) were cultured in the presence of 30 lM 5-bromo-2#-deoxyuridine (BrdU) (Roche, Manheim, Germany) for 18 h, followed by 3 h in the presence or absence of 30 nM mitomycin C (MMC; Sigma-Aldrich, Steinheim, Germany), 0.1 lM methyl methanesulfonate (MMS; Fluka Chemie, Buch, Switzerland) or 3 Gy of c-ray. After another 24 h in culture, colcemid was added to a final concentration of 20 ng/ml for 4 h and the cells were collected to prepare chromosome spreads (11) . SCEs were counted in at least 39 metaphase spreads of each treatment and genotype.
For the enumeration of micronuclei, primary MEFs at early passages (passage 3) of the two genotypes (PARG þ/þ and PARG 110
) from the same litter were used. Cells (1.3 Â 10 5 ) were seeded onto coverslips in complete Dulbecco's modified Eagle's medium containing 10% fetal calf serum on the day before treatment with 3 Gy of c-ray or 30 nM MMC for 2 h at 37°C. After 24 h, the cultures were washed in phosphate-buffered saline (PBS) and fixed for 5 min in 2% paraformaldehyde in PBS, permeabilized in 0.5% Triton X-100 and 70% ethanol for 10 min. After the final PBS wash, coverslips were mounted in slides with Vectashield containing 4#,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA). Triplicate samples of each genotype were prepared for each treatment and 1000 cells of each sample were counted for micronuclei. The treatment of cells and the screening of micronuclei were carried out by a double-blind approach.
Cytogenetic analysis
Metaphase chromosomal spreads were labeled with a telomere probe and visualized for chromosomal aberrations as described previously (6) . Early passages (passage 3) of primary MEFs of littermates were used.
Cell cycle analysis
Primary MEF cells (passage 3) were stained with propidium iodide (0.42 mg/ml) according to the manufacturer's manuals and analyzed with a dual-laser flow cytometer (FACS; Becton Dickinson, Le Pont de Claix, France). To analyze the BrdU-positive cell cycle profile, primary MEF cells were arrested by a treatment with 2 mM thymidine for 16 h followed by a treatment of aphidicolin-1 (Aph-1; Sigma-Aldrich) (1 lg/ml). After removing the drug, the cells were labeled with BrdU for 2 h before their harvest. For the flow cytometry analysis, harvested cells were fixed with cold ethanol and then incubated with 0.08% pepsin at 37°C for 20 min to isolate nucleus pellets. The nuclei were denatured with 2 M HCl and neutralized with 0.1 M Na-borate before pretreating them with immunofluorescence assay solution (10 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, pH 7.4; 150 mM NaCl; 4% fetal calf serum and 0.1% sodium azide) and Tween 20. The nucleus pellets were stained with anti-BrdU-fluorescein isothiocyanate antibody (B44 clone, 20 ll/10 6 cells; Becton Dickinson) and counterstained with propidium iodide (100 lg/ml in PBS). The BrdU incorporation was analyzed by flow cytometry. The 'ModFIT LT' software (Verity, Topsham, ME) and 'CellQUEST' software (Becton Dickinson) were used for the quantification of cell populations in the cell cycle. þ/À intercrosses, were treated with or without 1 lm/ml Aph-1 for 3 h and the cells were immunostained with a polyclonal antibody against pericentrin (1:150 dilution, PRB-432C; Covance, Leed, UK) and a monoclonal antibody against c-tubulin (1:200 dilution, GTU-88C; Sigma-Aldrich), which were conjugated with fluorescein isothiocyanate (1:200 dilution; Sigma-Aldrich) and Cy-3 (1:200 dilution; Sigma-Aldrich), respectively, as described previously (31) . The centrosomes that were stained positively with both antibodies were counted for analysis. At least 200 cells were analyzed from each genotype and each treatment.
Immunofluorescence analysis of cells
To monitor the Rad51 focus formation after the replication fork stall, primary MEFs were synchronized by the thymidine block and treated with 2 mM hydroxyurea (HU) for 3 h as described previously (32) . Briefly, cells were fixed at various time points after the removal of HU, stained with the polyclonal antiRad51 antibody (1:200 dilution; kindly provided by Steve West, Cancer Research UK, London, UK) and visualized by the Cy3-conjugated secondary antibody (1:200 dilution; Sigma-Aldrich). The slides were mounted in Vectashield containing 4#,6-diamidino-2-phenylindole (Vector Laboratories). Cells containing more than five foci were regarded as Rad51 foci positive.
Carcinogenesis in mice PARG 110
À/À mice (19) and wild-type (PARG 110
) mice in the pure 129/Sv background were set up for large cohort groups. Animals at 2 weeks of age were injected intraperitoneally with a single dose of 25 lg/g body wt of diethylnitrosamine (DEN; Sigma-Aldrich), which was freshly dissolved in sterile 0.9% saline. Controls were given saline only. At various time points after the DEN injection, a full necropsy was performed. A histopathological analysis was carried out on 3 lm-thick sections after hematoxylin and eosin staining. All animal experiments were approved by and performed in accordance with the guidelines of the International Agency for Research on Cancer's Animal Care and Use Committee.
Results
PARG is involved in DNA repair of both DNA SSBs and double-strand breaks PARG 110 À/À MEF cells and PARG À/À ES cells show an enhanced lethality after the treatment with various genotoxic agents (19, 28, 29) . To examine the effect of PARG 110 deletion on general DNA repair, we performed an alkaline Comet assay [that monitors the repair of both SSBs and double-strand breaks (DSBs)]. The repair capacity of PARG 110 À/À primary MEFs was monitored at various time points after DNA damages. After the hydrogen peroxide (H 2 O 2 ) treatment, the damage level (median ± SEM) of tail moments of wild-type and PARG-mutant cells are comparable: 28.5 ± 6.6 lm for wild-type and 27.5 ± 6.4 lm for PARG-mutant cells. Half an hour after H 2 O 2 treatment, $90% of the DNA damage was unrepaired in PARG 110 À/À cells, whereas only 43% remained unrepaired in wild-type (PARG þ/þ ) cells (P , 0.01). After 1 h, $40% of the breaks in PARG 110 À/À cells and 11% of the breaks in wild-type remained (P , 0.01, Figure 1A ). We also treated cells with 20 Gy of c-ray irradiation and found that the median ± SEM value of tail moments was 68.6 ± 7.1 lm for wild-type and 61.2 ± 3.5 lm for PARG 110 À/À cells. Fifteen minutes later, the remaining DNA breaks were significantly higher (82%) in mutant cells compared with wild-type cells (32%) (P , 0.01, Figure 1B ). This delayed repair of DNA damage in mutant cells was found at all time points examined throughout 24 h of observation. The repair efficiency in PARG 110 -mutant cells showed $30% or less of that in the wild-type controls at any given time point ( Figure 1B ). These alkaline Comet assay results suggest that a longer time is required for the repair of both SSBs and DSBs in PARG-deficient cells.
PARP1 is a major component of the base excision repair pathway and plays an important role in SSB repair (26, 27) . To further substantiate if PARG is involved in DSBs, we tested by the colony formation assay the sensitivity of PARG 110 À/À MEFs (19) to various concentrations of adriamycin. In response to this drug, PARG 110 À/À cells formed fewer colonies compared with wild-type controls ( Figure 1C and D), suggesting that PARG-mutant cells are hypersensitive to DSBs. Interestingly, the ataxia telangiectasia mutated (ATM) inhibitor KU55933 enhanced the cell killing by adriamycin in PARG 110 À/À cells ( Figure 1C and D) and this suggests that poly(ADP-ribosyl)ation modulated by PARP1 and PARG is additive to the ATM pathway in response to DSBs. Taken together, these data indicate that nuclear PARG is involved in the repair pathways of both SSBs and DSBs.
Loss of PARG 110 causes a high rate of SCE To investigate the effect of an impaired DNA repair in PARG 110 deficiency on genome stability and cell cycle progression, we used early passages (passage 3) of primary MEFs in order to avoid chromosome aberrations acquired during immortalization and changes of cell PARG in genomic stability and carcinogenesis cycle profile. First, we examined the SCE formation in primary PARG 110 À/À MEFs. While the majority of wild-type (PARG þ/þ ) cells contained about four SCEs per genome, PARG 110 À/À cells contained about seven SCEs, an approximate increase of 43% (P 5 0.0008, Figure 2A ). When cells were treated with c-ray or MMC, the number of SCEs was increased in both wild-type (about seven SCEs after radiation and nine SCEs after MMC, respectively) and mutant fibroblasts [$9 SCEs after radiation and 12 SCEs after MMC (P 5 0.0005, Figure 2A) ]. We also treated cells with MMS, a classic alkylating agent known to activate PARP1. After the MMS treatment, the increase of SCE rates was the highest in both wild-type ($11 SCEs) and mutant fibroblasts ($14 SCEs). The increased magnitude was much higher in PARG 110 À/À cells compared with wild-type cells (P 5 0.001, Figure 2A ).
PARG 110
À/À fibroblasts contain more micronuclei We next enumerated micronuclei in primary PARG 110 À/À MEFs (passage 3). Cells from wild-type and mutant genotypes were either untreated or treated with MMC or c-ray. In the untreated group, PARG 110 À/À cells contained a slightly, but significantly, higher number of micronuclei (127 ± 2/1000 cells) compared with wild-type controls (108 ± 4/1000 cells) (P , 0.05, Figure 2B ). After treatment with c-ray or MMC, the number of micronuclei in both wild-type and mutant cells was significantly increased ( Figure 2B ). The magnitude of increase after MMC treatment was 1.86-fold in mutant cells compared with 1.53-fold in wild-type counterparts (P , 0.001, Figure 2B) . Similarly, the increase after c-irradiation was 1.79-fold in mutant versus 1.65-fold in wild-type cells (P , 0.001, Figure 2B ).
PARG deficiency leads to a high degree of chromosome aberrations
We also performed a cytogenetic analysis of the chromosome spreads of early passages ( 3) in contrast to 8.3% of wild-type cells (P , 0.001). Moreover, 6.6% of PARG 110 À/À cells contained spontaneous chromatid breaks/ fragments, whereas no chromatid breaks found in wild-type cells (P , 0.05, Figure 2C ). After MMC treatment, we observed a further higher incidence of chromosome or chromatid breaks/fragments (13.8%) and fusion (22.4%) in PARG 110 À/À cells, in contrast to 6.3% chromosome breaks and 10.4% fusions in wild-type cells under the same condition (P , 0.01, Figure 2C ). Taken together, these results demonstrate that PARG deficiency confers a high degree of genomic instability and that PARG-deficient cells are prone to genotoxic agent-induced genomic instability.
Abnormal centrosome amplification in PARG 110
À/À cells correlates with impaired S-phase transition The centrosome function is important for the chromosome transmission to the daughter cells in mitosis and therefore plays an important role in genome stabilization (33) . PARP inhibitors and PARP1 deletion have caused centrosome hyperamplification in cells (31) and PARG is localized in centrosomes (34) . We next investigated whether PARG 110 deletion would affect the numeral homeostasis of centrosomes. Exponentially growing primary PARG 110 À/À and wild-type MEFs (passages 3) were co-immunostained for c-tubulin and pericentrin ( Figure 3A) . We found that 18% of PARG 110 À/À MEFs PARG in genomic stability and carcinogenesis contained abnormal numbers (.2) of centrosomes compared with 6% of wild-type MEFs that had hyperamplified centrosomes (P , 0.01, Figure 3B ).
Because the centrosome cycle is normally coordinated with the cell cycle (33), we questioned whether the centrosome hyperamplification is coupled with an abnormal S-phase progression in PARG-mutant cells. A flow cytometry analysis of the spontaneously growing primary MEFs after BrdU labeling revealed $19.6% of mutant cells in S-phase, in contrast to 15.6% of wild-type cells ( Figure 3C ), suggesting that PARG-mutant cells have an abnormal accumulation or progression of the S-phase population. To further substantiate that the centrosome hyperamplification was due to altered S-phase, we treated cells with Aph-1 that inhibits DNA polymerase leading to S-phase arrest. We found that $34% of mutant cells and 22.7% of wild-type cells were in S-phase after Aph-1 treatment ( Figure 3C ). Aph-1 treatment increased the proportion of S-phase cells by 1.74-fold in mutant cells compared with 1.45-fold in wild-type counterparts. Concurrently, Aph-1 treatment increased the number of mutant cells containing hyperamplified centrosomes (.2) up to 58%, but only to 28% of wild-type cells (P , 0.01, Figure 3D ). The magnitude of increased abnormal centrosome amplification (.2 centrosomes) after Aph-1 treatment was 2.8-fold in mutant versus 2.1-fold in wild-type cells (P 5 0.001). Altogether, these data demonstrate that the abnormal centrosome duplication correlates with the enhanced S-phase arrest or delayed S-phase transition.
Elevated Rad51 focus formation in PARG 110
À/À cells in response to stalled replication forks Hypersensitivity to S-phase poison and increased SCEs in PARG 110 mutant cells promoted us to investigate whether PARG participates in handling the repair of damaged DNA replication processes. The formation and dislodgment of nucleoprotein filaments of Rad51, a major homologous recombination repair (HRR) molecule, is proposed to facilitate the repair of damaged replication forks (35, 36) . We next monitored the translocation of Rad51 to and from stalled replication forks. To this end, we challenged PARG 110 À/À MEFs with HU and investigated the repair of stalled replication forks. In the control experiment (without HU treatment), Rad51 foci were almost undetectable in confluent cultures (data not shown). In subconfluent cultures, a slightly high, but not statistically significant, number of Rad51 foci were found in PARG 110 À/À primary MEF cells compared with wildtype (PARG þ/þ ) cells (Figure 4A and B) . HU treatment, as expected, induced massive Rad51 foci in both wild-type and PARG 110 À/À primary MEF cells, but with a higher number of Rad51 foci in PARG 110 À/À cells ( Figure 4A and C). The scoring of Rad51 foci revealed that, in contrast to wild-type cells, PARG 110 À/À cells contained a significantly higher number of Rad51 foci (P , 0.01, Figure 4C ). At 0 h after HU treatment, 47% of the PARG 110 À/À cells contained !45 foci in comparison with 16% in wild-type controls (P , 0.01, upper panel of Figure 4C ). This suggests that more broken replication forks remained in PARG-mutant cells.
We also monitored the kinetics of the Rad51-mediated repair of replication damage. To this end, we followed the changes in Rad51 foci 6 h after the removal of HU and found that 30% of PARG 110 À/À cells contained 35-44 foci and 34% had 45-74 foci in contrast to 21 and 6%, respectively, in wild-type cells (P , 0.01, lower panel of Figure 4C ). Moreover, while the majority of PARG þ/þ cells contained 5-44 Rad51 foci, PARG 110 À/À cells maintained higher numbers (25-54) of Rad51 foci 6 h after HU release ( Figure 4C ). More Rad51 foci at 0 and 6 h post-HU treatment suggest that HRR mediated by Rad51 persists for a longer time in the absence of PARG 110 , presumably due to the cells' inability to resolve stalled replication forks in a timely and efficient manner. This correlates with the increased S-phase cells in PARG deficient background after replication poison (see Figure 3C ).
PARG 110
À/À mice are susceptible to carcinogen-induced hepatocelluar carcinoma To investigate the biological consequences of PARG 110 deficiencyinduced DNA repair defects and genomic instability in vivo, we next tested the susceptibility of PARG 110 À/À mice to tumorigenesis using a DEN-induced liver carcinogenesis model. At 52 weeks of posttreatment, macroscopic and microscopic analyses revealed that DEN treatment induced tumourigenesis in the liver of both PARG 110 À/À and wild-type mice ( Figure 5A and B) . Although there was no obvious difference in hepatocelluar carcinoma (HCC) incidences between PARG 110 À/À and wild-type mice at this stage, more liver adenomas were found in PARG 110 À/À mice ( Figure 5B ). At 72 weeks after DEN treatment, 11 PARG 110 À/À mice (73%) developed HCC, in contrast to only 6 mice (38%) in the wild-type group (P 5 0.045, Figure 5C ). At this time point, wild-type mice contained more, but not statistically significant, liver regeneration and adenomas compared with in PARG mutant mice ( Figure 5C ). None of the saline-treated mice of either genotypes developed HCC or adenoma (Figure 5B andC) . These data indicate that a deletion of PARG 110 probably disturbed the homeostasis of pADPr and renders a faster cancer progression in mice.
Discussion
Similar to PARP1 À/À mice and cells (4-7), PARG-deficient cells showed a compromised DNA repair and increased genomic instability, and mutant mice were prone to chemical-induced carcinogenesis. Comet assay reveals that PARG-deficient cells exhibited a slow joining of DNA breaks induced by H 2 O 2 and c-ray. PARG-deficient cells were also susceptible to cytotoxicity induced by adriamycin. Together with the previous observations that PARG 110 -deficient cells are hypersensitive to alkylating agents and c-irradiation (19, 28) and also to other genotoxic agents (29) , these observations place PARG in the cascade of DNA damage repair. The PARG-mediated repair pathway seems to have a non-redundant function with ATM-mediated DSB repair because the chemical inhibitor of ATM sensitize PARG 110
MEFs to adriamycin treatment. This is reminiscent of the report showing a synergistic effect of ATM and PARP1 in early embryonic development (37) . Therefore, a combination of an inhibition of PARG and the DSB repair pathway may enhance the efficacy of cancer cell killing.
How is PARG involved in DNA repair? One of the possibilities is through modulating the poly(ADP-ribosyl)ation of PARP1 and other repair proteins. For example, an impaired poly(ADP-ribosy)lation of the DNA repair molecules XRCC1, DNA polymerase b, and p53 affects their functions in base excision repair (4) . Moreover, PARP1 automodification and DNA repair have been positively correlated (38) . In this regard, the deletion of PARG 110 dramatically downregulates the automodification of PARP1 (19) . It is also possible that, by recycling pADPr into adenosine triphosphate, PARG participates in the regeneration of a local ATP pool that is useful for the ligation of damaged DNA (13, 40) . Insufficient poly(ADP-ribosy)lation may compromise the ATP supply to the DNA repair machinery (41) . The H 2 O 2 -induced cytotoxicity after short hairpin RNA knockdown of PARP1 or PARG can be rescued by supplementing methylpyruvate and alpha-ketoglutarate, which indicates that an energy failure may mediate cytotoxicity (42) .
Consistent with an inefficient DNA repair, PARG 110 -mutant cells exhibit a genomic instability, characterized by high levels of spontaneous SCE, micronuclei, chromosome aberration as well as centrosome hyperamplifications. These genomic instability markers are greatly elevated in response to genotoxic treatments, such as MMC, MMS, Aph-1 and c-radiation. These phenotypes are similar to that of PARP1-mutant cells (11) . Since the PARG 60 isoform is still present in PARG 110 À/À mice, the remaining PARG activity carried by PARG 60 (19) maintains a certain degree of homoeostasis of poly(ADPribosy)lation, which, however, may not be sufficient to cope with a high degree of DNA damage. This may be the reason why PARG 110 -mutant cells show hypersensitivity to acute exogenous DNA damage (e.g. colony formation capacity), but it is almost negligible in spontaneous cultures (Min,W. unpublished results). Moreover, the genomic stability in PARG-mutant cells is also sensitive to genotoxic treatment.
Another explanation for the genomic instability is that PARG plays a direct role in the repair of damaged replication forks and the deletion PARG in genomic stability and carcinogenesis of PARG affects this repair. Consistent with this hypothesis, we have found that Rad51 foci were accumulated in PARG-mutant cells after replication fork damage and presented at a higher level at 0 and 6 h after HU removal compared with wild-type controls. The persistence of Rad51 foci in PARG 110 À/À cells (see Figure 4 ) after HU suggests that more time is required for HRR complexes (e.g. Rad51) to repair damaged replication forks. Moreover, the high degree of SCEs in these mutant cells could be due to more cells, or stayed longer, in S-phase, which may facilitate an illegitimate HRR attempt, for example, performed by Rad51. Consistently, similar replication defects have also been observed in PARP1 null cells (32) . Since PARP1 automodification is greatly downregulated in PARG 110 À/À cells (19) , it is thus plausible that the accumulation and/or persistence of Rad51 foci is one of the consequences of compromised poly(ADPribosyl)ation that may modulate the ability of the repair protein complexes or S-phase checkpoint to solve the stalled replication forks. However, how PARG mechanistically regulates the reactivation of stalled replication forks requires further investigation.
The centrosome function plays an important role in genome stabilization (33) . Consistent with these findings, we have observed that PARG hypomorphic mutants exhibited a hyperamplification of centrosomes. How PARG regulates the centrosome replication and their number is currently unclear, but it is possible that the pADPr metabolism or as a component of the centrosome is involved in centrosome homeostasis. In this regard, PARP1 and PARP3 are localized in the centrosome (31, 42) ; coincidently, PARG is also found in centrosomes (34) . PARP1-null mutation and PARP inhibitors cause centrosome hyperamplification (31) . Moreover, we have observed that the centrosome hyperamplification is associated with the hypersensitivity to S-phase poisons, suggesting that the reversible poly(ADP-ribosyl)ation of centrosome-associated proteins may be required for proper coupling of centrosome amplification with cell cycle progression. For example, PARP1 has been found co-expressed with p53, a major player in centrosome amplification (31, 43) and genetically interacts with p53 to stabilize the genome and repress tumorigenesis (44, 45) .
Despite the genomic instability and DNA repair defects, PARG 110 À/À mice do not develop spontaneous tumors. It is possible that additional genetic mutations are necessary to confer a full malignancy. Interestingly, DEN treatment greatly induced numbers of HCC in PARG-mutant mice compared with wild-type control mice. Similarly, DEN also induced a high frequency of liver tumors in PARP1-knockout mice (data not shown). Other chemical carcinogens, for example, azoxymethane and nitrosamine also greatly induced tumorigenesis in the liver, colons and lung of PARP1 mice (6, 46, 47) . Moreover, p53 deficiency (6, 44, 48) or Ku80 þ/À haploinsufficiency (49) increased tumor incidence of PARP1 À/À mice. Thus, due to a downregulation of PARP1 automodification in PARG 110 À/À mice, the higher cancer susceptibility of PARG-deficient mice may be attributable to a partial loss of PARP1 function. Altogether, our findings establish the notion that a PARG-mediated homeostasis of poly(ADP-ribosy)lation is important in DNA repair, stabilizing the genome and thereby suppressing cancer susceptibility. Thus, a modulation of PARG activity may present an alternative approach to the development of pharmaceutical strategies to treat and/or prevent certain pathogenesis.
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